Valuation: Charles River Laboratories International, Inc.

Market Cap 1.16TCr 1.02TCr 946.43Cr 870.49Cr 1.63TCr 1,10600Cr 1.66TCr 11TCr 4.39TCr 55TCr 4.35TCr 4.25TCr 1,89600Cr P/E 2026 *
39.2x
P/E 2027 * 26.3x
Enterprise Value 1.34TCr 1.18TCr 1.09TCr 1.01TCr 1.89TCr 1,28000Cr 1.92TCr 13TCr 5.08TCr 63TCr 5.03TCr 4.92TCr 2,19300Cr EV / Sales 2026 *
3.48x
EV / Sales 2027 * 3.31x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
20/07 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
13/07 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
13/07 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
13/07 Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics MT
13/07 Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches CI
13/07 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
09/07 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07/07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
02/07 Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing MT
01/07 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
18/06 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
18/06 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
18/06 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
1 day-1.78%
1 week+1.76%
Current month-0.86%
1 month+5.46%
3 months+34.64%
6 months+6.17%
Current year+14.11%
1 week 194.95
Extreme 194.95
200.8
1 month 191.45
Extreme 191.45
203.3
Current year 127.95
Extreme 127.95
203.3
1 year 124.25
Extreme 124.25
203.3
3 years 87.7
Extreme 87.7
251.8
5 years 87.7
Extreme 87.7
388
10 years 59.83
Extreme 59.829
388
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-1.78%+1.76% - - 1.08TCr
+0.14%-0.67%-0.88%+11.02% 4.77TCr
-2.24%+0.31%+393.45%+615.13% 4TCr
+1.40%+3.69%+12.21%+46.79% 3.62TCr
+13.94%+20.49%+22.85%+7.42% 3.56TCr
-0.73%+3.38%+4.94%+41.45% 2.79TCr
+0.40%-0.30% - - 1.67TCr
-3.12%+7.39%+26.03%+124.08% 1.65TCr
+2.39%-1.64%+4.74%+9.95% 1.32TCr
+6.79%+8.17%-4.97%-28.52% 1.29TCr
Average +1.72%+2.97%+57.30%+103.42% 2.74TCr
Weighted average by Cap. +1.94%+2.54%+76.11%+130.59%

Financials

2026 *2027 *
Net sales 384.83Cr 337.72Cr 314.49Cr 289.26Cr 542.23Cr 37TCr 551.53Cr 3.73TCr 1.46TCr 18TCr 1.44TCr 1.41TCr 63TCr 392.31Cr 344.29Cr 320.6Cr 294.88Cr 552.78Cr 37TCr 562.25Cr 3.8TCr 1.49TCr 19TCr 1.47TCr 1.44TCr 64TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.72TCr 41Cr 276.44Cr 108.2Cr 1.35TCr 107.04Cr 104.73Cr 4.67TCr 42Cr 37Cr 34Cr 31Cr 59Cr 3.99TCr 60Cr 404.6Cr 158.37Cr 1.98TCr 156.67Cr 153.28Cr 6.83TCr
Net Debt 181.35Cr 159.16Cr 148.21Cr 136.32Cr 255.53Cr 17TCr 259.92Cr 1.76TCr 688.22Cr 8.59TCr 680.84Cr 666.13Cr 30TCr 138.52Cr 121.57Cr 113.2Cr 104.12Cr 195.18Cr 13TCr 198.53Cr 1.34TCr 525.67Cr 6.56TCr 520.03Cr 508.8Cr 23TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
28/26/28 €196.10 -1.78%
27/26/27 €199.65 -0.57%
24/26/24 €200.80 +3.00%
23/26/23 €194.95 +1.83%
22/26/22 €191.45 -0.65%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
240.43USD
Average target price
230.93USD
Spread / Average Target
-3.95%

Quarterly revenue - Rate of surprise